They Ran Nattokinase Against a Statin. The Enzyme Won
SubscribeSign in
They Ran Nattokinase Against a Statin. The Enzyme Won
Sayer Ji<br>Jul 17, 2026
31
13
Share
A landmark randomized trial put a fermented-soybean enzyme head-to-head with simvastatin — and on the one measure that predicts heart attacks and strokes, the pennies-a-day enzyme shrank plaque more than three times as much as the drug.
Last year I wrote about the 1,062-patient nattokinase study that showed a fermented-soybean enzyme reversing arterial plaque — but only at a high enough dose. Readers asked the obvious question: fine, but how does it stack up against the drug my cardiologist actually prescribes?<br>It turns out someone ran exactly that experiment. And almost nobody in the West has heard about it, because it was published in Chinese.<br>The trial nobody talks about
In 2017, researchers at Sun Yat-sen University did something the statin industry does not go out of its way to fund. They took 82 patients with carotid plaque and high cholesterol, randomized them, and gave one group a statin and the other group nattokinase — then imaged their arteries 26 weeks later to see whose plaque actually shrank (Ren et al., National Medical Journal of China, 2017).
Simvastatin, 20 mg/day — a bread-and-butter statin dose
Nattokinase, 6,000 FU/day — a fermented-soybean enzyme you can buy without a prescription
Here is what the ultrasound showed at the end.<br>Plaque size, nattokinase group: down 36.6%.<br>Plaque size, statin group: down 11.5%.<br>The enzyme beat the drug by more than three to one on the thing that clogs arteries and kills people. Statistically significant. Not close (Ren et al., 2017).<br>Now the part that should end the LDL debate
The statin did win on cholesterol. Simvastatin dropped LDL, total cholesterol, and triglycerides harder than nattokinase did. If lowering LDL were the same thing as treating atherosclerosis — the premise of the last forty years of cardiology — the statin group should have had less plaque.<br>They had more than three times as much.<br>And nattokinase did one more thing the statin couldn’t: it significantly raised protective HDL. Simvastatin didn’t move it at all (Ren et al., 2017).<br>The researchers then checked whether nattokinase’s plaque regression tracked with its cholesterol-lowering. It didn’t (r=0.35, P=0.09). The plaque melted away through a mechanism that had essentially nothing to do with the LDL number (Ren et al., 2017).<br>Sit with that. The drug that lowered the number most cleared the least plaque. The whole “lower LDL, save the artery” edifice assumes those are the same event. This trial says they aren’t.<br>Why an enzyme does what a statin can’t
Nattokinase isn’t a cholesterol drug. It’s a clot-dissolving enzyme from natto, the traditional Japanese fermented soybean. It chews through fibrin directly, switches on your body’s own clot-busting system, and disables PAI-1, the molecular brake that keeps clots from dissolving (Urano et al., J Biol Chem, 2001). In animal models it’s about four times more powerful than the body’s own plasmin (Fujita et al., 1995).<br>Statins throttle the supply of cholesterol. Nattokinase goes to work on the artery itself. One massages a lab value. The other appears to clean the pipe.<br>“But the big trial found nothing”
Whenever nattokinase comes up, someone drops the NAPS trial — a 3-year, placebo-controlled USC study of 265 people that found no effect on plaque (Hodis et al., 2021). Case closed, they say.<br>Except: NAPS used 2,000 FU a day.<br>Ren used 6,000. The 1,062-patient study used 10,800 — and specifically showed that 3,600 FU/day did nothing, while 10,800 reversed plaque (Chen et al., 2022). There’s a dose threshold, and it’s well above what the “definitive” negative trial tested.<br>So NAPS didn’t disprove the plaque studies. It confirmed the floor. Below the threshold, you get the standard commercial dose, and you get nothing — exactly what NAPS found. The trials aren’t fighting each other. They’re drawing the same dose-response curve. The people waving NAPS around are, without realizing it, proving the dose argument.<br>I’ll be honest about the rest of the caveats, because I’d rather you hear them from me than from a debunker. Ren’s trial had no placebo group. The big 2022 study was retrospective and had manufacturer-linked co-authors. Nobody has run a trial counting heart attacks and deaths. This is not “settled.” Don’t throw away your medication on the strength of it.<br>But none of that erases a 3-to-1 plaque advantage over a statin in a randomized trial, or the dose-response signal that keeps reappearing across studies on two continents.
Why You Will Never See Nattokinase Advertised On Your TV
So why hasn’t someone run the billion-dollar trial that would settle this?<br>Because you can’t patent a soybean. Nattokinase has been eaten for centuries, it’s cheap, it’s safe at normal doses, and no company can own it. No one spends nine figures proving out a molecule their competitors can...